Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
Applicability of a Cellular Level Resolution Full-field OCT Image System (AMO, Taiwan) for the Diagnosis of Pigmented and Non-pigmented Skin Tumors
Apollo Medical Optics, Ltd
200 participants
Oct 21, 2021
OBSERVATIONAL
Summary
The incidence of skin cancer has been continuously increasing over the past decades und the number of non melanoma skin cancer is well as melanoma is still going to increase. Invasive biopsy and histological examination represents the gold standard in diagnosis of benign and malignant skin tumors. However, novel technologies such as reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) have been introduced in dermatology. Multiple studies have shown the applicability of both technologies for diagnosis of skin tumors as well as other skin diseases and to increase the specificity of diagnosis resulting in the reduction of unnecessary biopsies. New technological developments resulted in a high resolution OCT scanner (AMO, Taiwan), which allows vertical and horizontal evaluation (3D) of the skin at cellular resolution and up to a depth of around 400 μm and thus combines the advantages of both above mentioned techniques. ApolloVue® S100 Image System is a FDA-cleared 510(k) Class II medical device. Other non-invasive imaging method (reflectance confocal microscopy and conventional optical coherence tomography) will be used to evaluate a subset of skin lesions.
Eligibility
Inclusion Criteria4
- Patients aged > 18 years
- Willingness to participate in this study including the assessment with high resolution OCT
- Skin lesion/tumor with suspicion for skin cancer that requires skin biopsy or complete excision
- Benign skin tumor that is scheduled for excision due to suspicion, irritation or for cosmetic reason
Exclusion Criteria3
- Patients aged < 18 years
- Any unstable medical or psychological conditions
- Unwillingness to participate in this study including the assessment with high resolution OCT
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Device: ApolloVue® S100 Image System
Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05068310